INTRODUCTION
An exposure that might place health care worker (HCW) at risk for blood-borne infection is defined as a percutaneous injury (e.g., a needlestick or cut with a sharp object) or contact of mucous membrane or nonintact skin (e.g., exposed skin that is chapped, abraded, or afflicted with dermatitis) with blood, tissue, or other body fluids that are potentially infectious. The commonest health-care related infections are human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). The other pathogens which can be transmitted through occupational exposure are: [1] • Cytomegalovirus • Epstein-Barr virus • Parvovirus
• Human T-cell lymphotropic virus • Treponema pallidum (syphilis)
• Plasmodium spp.
• Babesia • Trypanosoma • Toxoplasma spp.
• Leishmania • Microfilaria.
Centre for Disease Control has estimated that 5.6 million HCW are at risk of occupational exposure to this blood-borne viruses [2] and more than 380,000 percutaneous exposures occur each year. [3] A significant number of occupational exposures are under reported due to lack of understanding of the risk involved.
Nurses are reported to have the highest risk of exposure followed by doctors (registrars and fellows), nonlaboratory technicians, respiratory therapists, certified nursing assistants, and home aides. [4] A 3-fold increased risk of needle stick injuries (NSIs) is associated with long work hours and sleep deprivation. [5] The most common devices involved in causing NSI are disposable syringes. These sharp devices most commonly cause injury during suturing, drawing venous blood, and administering injections. 
RISK OF HUMAN IMMUNODEFICIENCY VIRUS SEROCONVERSION
The average risk of seroconversion for HIV is 0.3% after an NSI without postexposure prophylaxis (PEP) and that after a mucosal exposure is 0.09% following exposure to blood or body fluid of an HIV-infected an individual.
[6] A terminally ill patient of HIV infection can lead to increased risk of transmission. [7] The risk of transmission of HBV after an NSI depends on the immune status of the HCW and the Hepatitis B e antigen (HBeAg) status of the source. If the source is HBeAg positive which indicates active replication of the virus, the risk of transmission is as high as 22-40%. However, when the source is HBeAg negative the transmission risk significantly reduces to 1-6%. [8] The risk of HCV seroconversion after NSI from a patient with HCV infection is 1.8%. [9] 
AVOIDING NEEDLE STICK INJURY AND INFECTION
The single most effective method of avoiding NSI is to avoid re-capping and re-sheathing. The puncture proof container should be in close proximity for discarding sharps. It is equally important to wear personal protective equipment while performing any procedure. A decrease in the incidence of NSI is seen with the use of needle-free delivery mechanisms such as jet injection devices. [10] Needles with safety barrel and with blunt tips can reduce the frequency of NSI. Adequate training in safety procedures and improved compliance with safe operating rooms behavior can significantly reduce injury and infection rates.
ROLE OF VACCINATION
Every hospital employee or any healthcare personnel who is at the risk of accidental exposure to blood or blood products should be vaccinated against hepatitis B. Three doses of hepatitis B vaccination should be given to each hospital employee at 0, 1, and 6 months. Anti-hepatitis B surface (HBs) titer should be known to each person after vaccination which should preferably be done after 1-2 months of completing the vaccination. [9] There is no preventive vaccination yet available for HCV and HIV.
POSTEXPOSURE PROPHYLAXIS
Management of health care personnel immediately after an exposure to blood and other infectious body fluids is essential in reducing the risk of transmission. Institutional policies are therefore important in further managing the HCW. The following steps are to be followed: 
Evaluation of source
• HIV, HBV, and HCV ELISA of the source • If all the three serology testing are negative, counsel the exposed person, and no further intervention required
• If the exposed person is not immunized against hepatitis B, initiate the vaccination as per protocol.
Evaluation of the exposed person

When source is human immunodeficiency virus positive
• HIV ELISA of the exposed • Complete blood count, renal and liver function test.
PEP should be offered to all the persons exposed to body fluids with potential for HIV transmission.
Exposure with potential transmission includes parenteral or mucosal exposure of blood, breast milk, genital secretions, cerebrospinal fluid, amniotic fluid, peritoneal fluid, synovial fluid, pericardial fluid, and pleural fluid. Exposure to tear, saliva, urine, feces, and sweat are not considered to have the potential of transmission provided it is not mixed with blood.
[11]
WHO [12] and NACO [11] have laid down recommendations for PEP.
WHO recommends a three-drug regime in all situations.
Regimen advised is tenofovir (TDF) + lamivudine (3TC) or emtricitabine (FTC) + lopinavir/ritonavir (LPV/r) or atazanavir/ritonavir (ATV/r).
Raltegravir, darunavir/ritonavir, or efavirenz can be considered as alternative option.
NACO
[11] has recommended two-drug regime (basic), or three-drug regime (expanded) based on the nature of the exposure and risk of the source to transmit the illness.
The nature of exposure • Mild -if there is small volume exposure to mucous membrane or nonintact skin • Moderate -large volume of exposure to mucous membrane or nonintact skin and percutaneous superficial exposure with solid needle • Severe -percutaneous exposure with large volume.
Risk of the source to transmit illness
• Low risk -when they are clinically asymptomatic • High risk -when the patient is symptomatic clinically.
NACO divides the PEP to basic or expanded regime according to the nature of exposure and risk of the source [ Table 1 ].
Basic regime with two drugs is zidovudine/tenofovir and lamivudine.
The expanded regime is basic regime + LPV/r or nelfinavir or indinavir.
The US public health service and British HIV Association guidelines recommend tenofovir/emtricitabine with raltegravir as the preferred regimen for PEP. [13, 14] Timing of postexposure prophylaxis It should be initiated as early as possible. Less effective when used beyond 72 h. [10] It should be taken for 4 weeks. [15, 16] • Counseling of the exposed
• About the side effects of the drugs • Risk of exposure • To use barrier protection for 6 weeks.
• Expert opinion should be sought if
• Source is unknown • Source is antiretroviral experienced and is known or suspected to have resistance • Exposed person is pregnant or lactating. Table 2 . [11, 12] When source is hepatitis B virus positive [17] If exposed person is vaccinated • Anti-hepatitis B surface antigen (HBs) antibodies.
Doses of drug used for PEP as shown in
• Titre <10 IU -immunoglobulins (0.06 ml/kg) + hepatitis B booster When source is hepatitis C virus positive [18, 19] • Test HCV status of the exposed person • No PEP available.
Follow-up of HCW is required and done as shown in Table 3 .
[12]
CONCLUSION
Prevention of occupational injuries remains the best method of preventing the risk of transmission of these blood borne viruses. Each patient who visits a health care setting should be treated as infectious and hence personal protective equipment should be used by the HCW. Among the three important blood-borne viral diseases, hepatitis B is a vaccine preventable disease and hence immunization against hepatitis B and subsequently the anti-HBs titers done 1-2 months after the third dose of hepatitis B immunization is strongly recommended for all health care professional.
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